Dr Chris Mann, Scientific & Regulatory Director at Asphalion delivered lectures including discussions on the Accelerating Research & Development for Advanced Therapies (ARDAT) project, as part of the The University of Sheffield’s Advanced Cell and Gene Therapies MSc course at the Sheffield Institute of Translational Neuroscience, UK.
A new year, new classes, and a deep dive into advanced therapies, including discussions on the Accelerating Research & Development for Advanced Therapies (ARDAT) project, as part of the The University of Sheffield’s Advanced Cell and Gene Therapies MSc course at the Sheffield Institute of Translational Neuroscience (SITraN).
Over the course of the year, students will dive into the cutting-edge world of cell and gene therapies, with guidance from Professors Mimoun Azzouz and Janine Kirby. Topics include rare inherited diseases, personalized treatments, molecular biology techniques, and translating therapies from the lab to the market.
The ARDAT project, a collaboration of 32 international partners from academia, industry, and small/medium enterprises, is focused on advancing our knowledge in viral gene/ cell therapy to accelerate the development of new treatments for rare diseases.
It was an exciting opportunity last week for ASPHALION’s expert Christopher Mann to share insights with a great group of students, and none of them will ever look at pineapple pizza the same way again!
If you want to know more, have a look at the website for details of the next course.